P32261
Gene name |
Serpinc1 (At3) |
Protein name |
Antithrombin-III |
Names |
ATIII, Serpin C1 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:11905 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for P32261
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-P32261-F1 | Predicted | AlphaFoldDB |
41 variants for P32261
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388511151 | 18 | L>H | No | EVA | |
| rs238171425 | 28 | G>A | No | EVA | |
| rs3388511804 | 30 | A>T | No | EVA | |
| rs3413058601 | 41 | C>S | No | EVA | |
| rs3388511386 | 48 | I>L | No | EVA | |
| rs3388509852 | 50 | V>M | No | EVA | |
| rs3388511771 | 51 | N>T | No | EVA | |
| rs3388511218 | 52 | P>H | No | EVA | |
| rs3388510778 | 75 | E>D | No | EVA | |
| rs3388509817 | 79 | R>L | No | EVA | |
| rs3388508585 | 86 | K>N | No | EVA | |
| rs3388508396 | 89 | S>L | No | EVA | |
| rs13460842 | 91 | F>L | No | EVA | |
| rs3388511421 | 122 | M>K | No | EVA | |
| rs3388508366 | 128 | C>Y | No | EVA | |
| rs3388510787 | 129 | N>K | No | EVA | |
| rs3388509436 | 135 | L>Q | No | EVA | |
| rs3388506998 | 136 | M>R | No | EVA | |
| rs3388509447 | 142 | D>V | No | EVA | |
| rs3413145644 | 150 | D>Y | No | EVA | |
| rs3388507012 | 154 | F>L | No | EVA | |
| rs227108953 | 172 | D>N | No | EVA | |
| rs3388512922 | 174 | V>I | No | EVA | |
| rs3388511345 | 214 | Q>R | No | EVA | |
| rs3388508165 | 259 | K>* | No | EVA | |
| rs3388512965 | 261 | K>N | No | EVA | |
| rs3388510418 | 269 | K>M | No | EVA | |
| rs261982908 | 271 | P>S | No | EVA | |
| rs3388508572 | 305 | L>M | No | EVA | |
| rs233796502 | 347 | T>I | No | EVA | |
| rs3388509786 | 361 | G>D | No | EVA | |
| rs3388511370 | 368 | L>M | No | EVA | |
| rs13460840 | 371 | M>T | No | EVA | |
| rs49991990 | 376 | L>I | No | EVA | |
| rs3388506037 | 383 | Q>K | No | EVA | |
| rs3388509778 | 413 | S>C | No | EVA | |
| rs3388509850 | 413 | S>N | No | EVA | |
| rs3388508347 | 417 | A>V | No | EVA | |
| rs3388507074 | 419 | T>I | No | EVA | |
| rs3388509871 | 450 | L>P | No | EVA | |
| rs3388511742 | 455 | F>I | No | EVA |
No associated diseases with P32261
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| collagen-containing extracellular matrix | An extracellular matrix consisting mainly of proteins (especially collagen) and glycosaminoglycans (mostly as proteoglycans) that provides not only essential physical scaffolding for the cellular constituents but can also initiate crucial biochemical and biomechanical cues required for tissue morphogenesis, differentiation and homeostasis. The components are secreted by cells in the vicinity and form a sheet underlying or overlying cells such as endothelial and epithelial cells. |
| extracellular space | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| heparin binding | Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. |
| identical protein binding | Binding to an identical protein or proteins. |
| protease binding | Binding to a protease or a peptidase. |
| serine-type endopeptidase inhibitor activity | Binds to and stops, prevents or reduces the activity of serine-type endopeptidases, enzymes that catalyze the hydrolysis of nonterminal peptide bonds in a polypeptide chain; a serine residue (and a histidine residue) are at the active center of the enzyme. |
4 GO annotations of biological process
| Name | Definition |
|---|---|
| blood coagulation | The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers. |
| negative regulation of endopeptidase activity | Any process that decreases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins. |
| regulation of blood coagulation, intrinsic pathway | Any process that modulates the frequency, rate or extent of blood coagulation, intrinsic pathway. |
| response to nutrient | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nutrient stimulus. |
35 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9N2I2 | SERPINA5 | Plasma serine protease inhibitor | Bos taurus (Bovine) | PR |
| A6QPQ2 | SERPINA3-8 | Serpin A3-8 | Bos taurus (Bovine) | PR |
| A2I7N1 | SERPINA3-5 | Serpin A3-5 | Bos taurus (Bovine) | PR |
| Q1JPB0 | SERPINB1 | Leukocyte elastase inhibitor | Bos taurus (Bovine) | PR |
| P13909 | SERPINE1 | Plasminogen activator inhibitor 1 | Bos taurus (Bovine) | PR |
| Q9TTE1 | SERPINA3-1 | Serpin A3-1 | Bos taurus (Bovine) | PR |
| P41361 | SERPINC1 | Antithrombin-III | Bos taurus (Bovine) | PR |
| O73790 | SERPINB10 | Heterochromatin-associated protein MENT | Gallus gallus (Chicken) | PR |
| P05121 | SERPINE1 | Plasminogen activator inhibitor 1 | Homo sapiens (Human) | PR |
| Q9UK55 | SERPINA10 | Protein Z-dependent protease inhibitor | Homo sapiens (Human) | PR |
| P05155 | SERPING1 | Plasma protease C1 inhibitor | Homo sapiens (Human) | PR |
| P08697 | SERPINF2 | Alpha-2-antiplasmin | Homo sapiens (Human) | PR |
| Q86WD7 | SERPINA9 | Serpin A9 | Homo sapiens (Human) | PR |
| P07093 | SERPINE2 | Glia-derived nexin | Homo sapiens (Human) | PR |
| Q96P15 | SERPINB11 | Serpin B11 | Homo sapiens (Human) | PR |
| P01011 | SERPINA3 | Alpha-1-antichymotrypsin | Homo sapiens (Human) | PR |
| P01008 | SERPINC1 | Antithrombin-III | Homo sapiens (Human) | PR |
| P12388 | Serpinb2 | Plasminogen activator inhibitor 2, macrophage | Mus musculus (Mouse) | PR |
| Q07235 | Serpine2 | Glia-derived nexin | Mus musculus (Mouse) | PR |
| Q5SV42 | Serpinb1c | Leukocyte elastase inhibitor C | Mus musculus (Mouse) | PR |
| Q80X76 | Serpina3f | Serine protease inhibitor A3F | Mus musculus (Mouse) | PR |
| Q8BYY9 | Serpina3b | Serine protease inhibitor A3B | Mus musculus (Mouse) | PR |
| Q9D154 | Serpinb1a | Leukocyte elastase inhibitor A | Mus musculus (Mouse) | PR |
| Q9JK88 | Serpini2 | Serpin I2 | Mus musculus (Mouse) | PR |
| Q8CDC0 | Serpinb13 | Serpin B13 | Mus musculus (Mouse) | PR |
| P22777 | Serpine1 | Plasminogen activator inhibitor 1 | Mus musculus (Mouse) | PR |
| Q5I2A0 | Serpina3g | Serine protease inhibitor A3G | Mus musculus (Mouse) | PR |
| P29524 | Serpinb2 | Plasminogen activator inhibitor 2 type A | Rattus norvegicus (Rat) | PR |
| Q6P734 | Serping1 | Plasma protease C1 inhibitor | Rattus norvegicus (Rat) | PR |
| P05545 | Serpina3k | Serine protease inhibitor A3K | Rattus norvegicus (Rat) | PR |
| P07092 | Serpine2 | Glia-derived nexin | Rattus norvegicus (Rat) | PR |
| Q62975 | Serpina10 | Protein Z-dependent protease inhibitor | Rattus norvegicus (Rat) | PR |
| O48706 | At2g26390 | Serpin-Z3 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9M1T7 | At3g45220 | Serpin-Z4 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9ZQR6 | At2g14540 | Serpin-Z2 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MYSPGAGSGA | AGERKLCLLS | LLLIGALGCA | ICHGNPVDDI | CIAKPRDIPV | NPLCIYRSPG |
| 70 | 80 | 90 | 100 | 110 | 120 |
| KKATEEDGSE | QKVPEATNRR | VWELSKANSR | FATNFYQHLA | DSKNDNDNIF | LSPLSISTAF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| AMTKLGACND | TLKQLMEVFK | FDTISEKTSD | QIHFFFAKLN | CRLYRKANKS | SDLVSANRLF |
| 190 | 200 | 210 | 220 | 230 | 240 |
| GDKSLTFNES | YQDVSEVVYG | AKLQPLDFKE | NPEQSRVTIN | NWVANKTEGR | IKDVIPQGAI |
| 250 | 260 | 270 | 280 | 290 | 300 |
| NELTALVLVN | TIYFKGLWKS | KFSPENTRKE | PFYKVDGQSC | PVPMMYQEGK | FKYRRVAEGT |
| 310 | 320 | 330 | 340 | 350 | 360 |
| QVLELPFKGD | DITMVLILPK | PEKSLAKVEQ | ELTPELLQEW | LDELSETMLV | VHMPRFRTED |
| 370 | 380 | 390 | 400 | 410 | 420 |
| GFSLKEQLQD | MGLIDLFSPE | KSQLPGIVAG | GRDDLYVSDA | FHKAFLEVNE | EGSEAAASTS |
| 430 | 440 | 450 | 460 | ||
| VVITGRSLNP | NRVTFKANRP | FLVLIREVAL | NTIIFMGRVA | NPCVN |